Email Updates

Search form

You are here

4 November 2016 VOLUME 17 ISSUE 44

Media Coverage

  • Smokers with HIV could see smoking shorten their lifespan more than the disease itself does, according to new research to be published in the Journal of Infectious Diseases. Researchers modeled the impact of HIV using the most up-to-date treatment and life expectancy data. They found that for adults who stick to their HIV treatment plan, smoking reduces life expectancy by about twice as much as the HIV itself does.

    November 3, 2016
    STAT
  • Researchers set out to evaluate whether changes in the use of condoms reflected increased adoption of serosorting (having sex only with those of similar HIV status) or biomedical preventions like antiretroviral treatment. Their report, published in May in the journal AIDS, concluded that condomless sex continues to increase among men who have sex with men, but “the trends are not explained by serosorting or ART.”

    November 3, 2016
    Advocate
  • The Israeli Health Ministry will begin a pilot program next month that will provide free HIV-prevention medication to at-risk population groups: gay men having unprotected sex with multiple partners, couples where one of the partners is HIV positive, drug addicts, and prostitutes.

    November 3, 2016
    The Tower
  • Russian health officials say one in 50 people in the country’s fourth-largest city is carrying the HIV virus....The central Russian city of Yekaterinburg suffers from an HIV epidemic, regional Deputy Health Minister Tatiana Savinova said, according to a statement widely reported by Russian media. The city of 1.5 million people has 27,000 residents, or 1.8 percent of the population, carrying the virus, she said.

    November 2, 2016
    CBS News
  • In September, world leaders pledged nearly US$13 billion to...the Global Fund to Fight AIDS, Tuberculosis and Malaria. In a time of significant global uncertainty and strife, this was a remarkable display of commitment to the health and well-being of the most vulnerable populations on the planet....But donor resources are not limitless....We need to marshal resources and leadership from the countries that, tragically, know them best – many of which are in Africa.

    November 1, 2016
    All Africa
  • A machine learning algorithm used to analyse electronic health records (EHRs) identified high-risk individuals who could potentially benefit from PrEP, according to a report presented this week at IDWeek 2016 in New Orleans. Out of 800,000 patients in a large EHR database, more than 8000 were found to be potential PrEP candidates.

    November 1, 2016
    aidsmap
  • As the global quest for an HIV vaccine continues, Linda-Gail Bekker explains the significance of the latest large-scale trial underway in South Africa.

    November 1, 2016
    The Conversation
  • PrEP Access In Europe, a report provided by the PrEP in Europe Initiative...has called for European governments to make the HIV preventative drug PrEP available to those at imminent risk as a matter of urgency... [and] to provide more information about PrEP and make it widely available to the public, so they can fully comprehend the advantages of the drug themselves.

    November 1, 2016
    Gay Times
  • HIV, viral hepatitis and tuberculosis can each be treated at an annual cost of just $90, Dr Andrew Hill told the 2016 International Congress on Drug Therapy in HIV Infection (HIV Glasgow), held 23-26 October...But Dr Hill cautioned that few policy makers or purchasers of anti-HIV drugs in Europe were aware of how cheaply generics can be manufactured. “...We need a lot more pricing transparency, which will have a cascade effect across therapeutic areas,” he said.

    November 1, 2016
    aidsmap
  • Atomo Diagnostics today announced it is the recipient of a US$2.6 million grant from the Bill & Melinda Gates Foundation to support development of a [next-generation] affordable, reliable and simple HIV rapid diagnostic test that will enable people in resource-poor countries to test themselves....A key program component will be engaging with public and private sector partners in developing countries to support commercial launch in key markets.

    October 31, 2016
    News-Medical
  • A new biologic medication - the first for HIV - is showing promise in treating patients with multidrug resistance, according to phase 3 research presented at IDWeek 2016. Administered intravenously once every two weeks, ibalizumab is a...monoclonal antibody, a genetically engineered molecule that coats immune system cells to protect them from HIV entry. Eighty-three percent of patients with multi-drug resistant HIV had a virologic response to the drug, according to the study.

    October 31, 2016
    News-Medical
  • In the absence of national screening guidelines, only 11% of HIV-positive gay and bisexual men in the US received anal pap smears to detect anal cancer or precancerous cell changes between 2009 and 2012, with disparities between patient groups and variations across centres, according to a presentation at IDWeek 2016 this week in New Orleans.

    October 31, 2016
    aidsmap
  • Tanzania has suspended community-based HIV/AIDS prevention programmes for gay men, the health minister said on Monday, in the latest crackdown on the high-risk group. Ummy Mwalimu, Tanzania's minister for health, said the government had received reports that some local non-governmental organisations were promoting and normalising same-sex relationships as part of their HIV programmes.

    October 31, 2016
    Reuters
  • History will be made this week, when the first participant in a large-scale HIV vaccine trial receives a shot of the vaccine, designed to prevent a strain of HIV prevalent in southern Africa.

    October 30, 2016
    News24
  • Facing “very low market demand,” GlaxoSmithKline has decided to pull out of the U.S. market with the HPV vaccine Cervarix. It’s a move that gives Merck a stranglehold on the market as public health officials work feverishly to boost vaccination rates....A sex stigma, safety concerns, antivaccine campaigns and other factors have hindered uptake for a vaccine class once anticipated to reel in $4 billion to $10 billion.

    October 28, 2016
    Fierce Biotech
  • A sexual health clinic in central London that offered to test drug levels in users of tenofovir/emtricitabine pre-exposure prophylaxis (PrEP) who had bought it online found adequate levels of both drugs in their blood, and no sample suggesting counterfeit drugs....Dr Nneka Nwokolo presented data from a sample of 234 Dean Street clinic [Soho, London] patients.

    October 26, 2016
    aidsmap
  • Insomnia, dizziness, headache and other central nervous system side-effects are occurring more frequently with everyday use of dolutegravir than clinical trials had suggested, and are most likely to occur in women, people over 60, and people starting abacavir at the same time, a German research group told the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) Tuesday.

    October 25, 2016
    aidsmap
  • The complexity of the needs of people living with HIV will continue to increase as the population ages, and clinicians need to go beyond thinking about co-morbidities to consider multi-morbidities – clusters of medical conditions which complicate one another – when caring for these people, Dr Edouard Battegay of University Hospital Zurich told the International Congress on Drug Therapy in HIV Infection (HIV Glasgow).

    October 25, 2016
    aidsmap

Published Research

Announcements